Asunto(s)
COVID-19/prevención & control , Costos de la Atención en Salud/ética , Asignación de Recursos para la Atención de Salud/ética , Recien Nacido Extremadamente Prematuro , Enfermedades del Prematuro/terapia , Cuidado Intensivo Neonatal/ética , Justicia Social/ética , COVID-19/economía , COVID-19/epidemiología , Toma de Decisiones Clínicas/ética , Toma de Decisiones Clínicas/métodos , Costos de la Atención en Salud/estadística & datos numéricos , Asignación de Recursos para la Atención de Salud/economía , Asignación de Recursos para la Atención de Salud/métodos , Humanos , Recién Nacido , Enfermedades del Prematuro/economía , Cuidado Intensivo Neonatal/economía , Cuidado Intensivo Neonatal/estadística & datos numéricos , Cuidados Paliativos/economía , Cuidados Paliativos/ética , Pandemias , Calidad de Vida , Justicia Social/economía , Valores Sociales , Estados Unidos/epidemiologíaRESUMEN
In a formal economic evaluation ancillary to the Caffeine for Apnea of Prematurity trial, caffeine was shown to reduce costs while simultaneously improving clinical outcomes. Although these results still apply, the current price of caffeine is substantially higher than when it was introduced. Such pharmaceutical price growth contributes appreciably to medical costs and inflation. In this review, the examples of caffeine and surfactant show how prices are determined for the neonatology formulary. Drivers include small market size, government-imposed barriers to competition designed to encourage innovation, high willingness-to-pay, failure of government buyers to exercise their market power, and asymmetries in knowledge about costs and effects between producers and patients. Many of these factors are exercised at the national policy or market levels. However, by conducting rigorous clinical trials and economic evaluations, neonatologists can still ensure that the drugs they prescribe are both efficacious and represent good use of societal resources.
Asunto(s)
Cafeína/economía , Cafeína/uso terapéutico , Citratos/economía , Citratos/uso terapéutico , Enfermedades del Prematuro/tratamiento farmacológico , Enfermedades del Prematuro/economía , Control de Costos , Análisis Costo-Beneficio , Costos de los Medicamentos , Humanos , Recién Nacido , Medicamentos bajo Prescripción/economíaAsunto(s)
Lactancia Materna/economía , Enfermedades del Prematuro/prevención & control , Unidades de Cuidado Intensivo Neonatal/economía , Leche Humana , Animales , Análisis Costo-Beneficio , Dieta , Femenino , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/economía , Recién Nacido de muy Bajo PesoRESUMEN
BACKGROUND: Intraventricular hemorrhage (IVH) disproportionately affects black neonates. Other conditions that are more common in black neonates, including low birth weight and preterm delivery, have been linked with residential racial segregation (RRS). In this study, we investigated the association between RRS and IVH. METHODS: A retrospective cohort of neonates born between 24 and 32 weeks' gestation was constructed by using birth certificates linked to medical records from California, Missouri, and Pennsylvania between 1995 and 2009. Dissimilarity, a measure of RRS indicating the proportion of minorities in the census tract of the mother in comparison to the larger metropolitan area, was linked to patient data, yielding a cohort of 70 775 infants. Propensity score analysis matched infants born to mothers living in high segregation to those living in less segregated areas on the basis of race, sociodemographic factors, and medical comorbidities to compare the risk of developing IVH. RESULTS: Infants born to mothers in the most segregated quartile had a greater risk of developing IVH compared with those in the lowest quartile (12.9% vs 10.4%; P < .001). In 17 918 pairs matched on propensity scores, the risk of developing IVH was greater in the group exposed to a segregated environment (risk ratio = 1.08, 95% confidence interval: 1.01-1.15). This effect was stronger for black infants alone (risk ratio = 1.16; 95% confidence interval: 1.03-1.30). CONCLUSIONS: RRS is associated with an increased risk of IVH in preterm neonates, but the effect size varies by race. This association persists after balancing for community factors and birth weight, representing a novel risk factor for IVH.
Asunto(s)
Población Negra , Hemorragia Cerebral/epidemiología , Enfermedades del Prematuro/epidemiología , Recien Nacido Prematuro/fisiología , Segregación Social/tendencias , Adulto , Hemorragia Cerebral/diagnóstico por imagen , Hemorragia Cerebral/economía , Ventrículos Cerebrales/diagnóstico por imagen , Estudios de Cohortes , Femenino , Edad Gestacional , Humanos , Recién Nacido , Enfermedades del Prematuro/diagnóstico por imagen , Enfermedades del Prematuro/economía , Masculino , Puntaje de Propensión , Estudios Retrospectivos , Estados Unidos/epidemiología , Adulto JovenRESUMEN
OBJECTIVE: This study examined the rate, severity, and cost of respiratory syncytial virus (RSV) hospitalizations among preterm infants 29 to 34 weeks gestational age (wGA) versus term infants before and after a 2014 change in the American Academy of Pediatrics policy for RSV immunoprophylaxis. STUDY DESIGN: Preterm (29-34 wGA) and term infants born from July 2011 to March 2017 and aged < 6 months were identified in a U.S. commercial administrative claims database. RSV hospitalization (RSVH) rate ratios, severity, and costs were evaluated for the 2011 to 2014 and 2014 to 2017 RSV seasons. Postpolicy changes in RSVH risks for preterm versus term infants were assessed with difference-in-difference (DID) modeling to control for patient characteristics and temporal trends. RESULTS: In the DID analysis, prematurity-associated RSVH risk was 55% greater in 2014 to 2017 versus 2011 to 2014 (relative risk = 1.55, 95% confidence interval: 1.10-2.17, p = 0.011). RSVH severity increased among preterm infants after 2014 and was highest among those aged < 3 months. Differences in mean RSVH costs for preterm infants in 2014 to 2017 versus 2011 to 2014 were not statistically significant. CONCLUSION: RSVH risk for preterm versus term infants increased after the policy change, confirming previous national analyses. RSVHs after the policy change were more severe, particularly among younger preterm infants.
Asunto(s)
Antivirales/uso terapéutico , Hospitalización/estadística & datos numéricos , Enfermedades del Prematuro/epidemiología , Recien Nacido Prematuro , Palivizumab/uso terapéutico , Infecciones por Virus Sincitial Respiratorio/epidemiología , Hospitalización/economía , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/prevención & control , Política Organizacional , Guías de Práctica Clínica como Asunto , Infecciones por Virus Sincitial Respiratorio/economía , Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas contra Virus Sincitial Respiratorio , Riesgo , Sociedades Médicas , Estados Unidos/epidemiologíaRESUMEN
OBJETIVO: Identificar las principales causas de ingresos y reingresos hospitalarios de recién nascidos prematuros y evaluar los costes que los reingresos generan entre los años 2000 y 2011 en el Hospital Virgen Del Camino (Pamplona), España. MÉTODOS: Estudio descriptivo, retrospectivo, con análisis de 297 niños prematuros que estuvieron ingresados en la UCI neonatal y reingresaron en algún servicio del hospital en cuestión, al menos una vez, en los 60 días tras el alta hospitalaria. RESULTADOS: La mayor parte de los casos (91,25%) presentaron un único reingreso. La estancia media de reingreso fue de 4,61 días. Las bronquitis y asma sin complicaciones constituyen la causa más común de reingreso. CONCLUSIÓN: Intentar que los padres permanezcan con sus hijos cuando éstos están hospitalizados les puede proporcionar una mayor formación acerca de las características normales de su hijo, de las enfermedades y problemas asociados a la prematuridad, haciendo con que los padres busquen ayuda médica en la inicial de la enfermedad pudiendo disminuir el riesgo de un posible reingreso hospitalario
OBJECTIVE: Identify the primary cause of the hospital admission and readmission of premature infants and evaluate the costs of the readmission between the years 2000 and 2011 in the Comunidade Foral de Navarra hospital in Pamplona, Spain. METHODS: This is a descriptive, retrospective study involving analysis of 297 premature infants who were admitted to the neonatal Intensive Care Unit and were subsequently readmitted at another division of the aforementioned hospital, at least once, during the sixty days after discharge. RESULTS: The majority of the cases studied (91.25%) were re-hospitalized only once, with an average stay of 4.61 days. Bronchiolitis and asthma were the most common cause for patient readmission. CONCLUSIONS: The author highlights the importance of parental presence during the child's hospitalization, as they can provide detailed information on the normal characteristics of their child and the potential health issues associated with prematurity. If the child presents any symptoms, the parents will know to seek medical help in the early stages, reducing the risk of complications and future hospitalizations
OBJETIVO: Identificar as principais causas de internação e reinternação hospitalar de recém-nascidos prematuros e avaliar os custos que estas reinternações geraram entre os anos de 2000 a 2011 no Hospital Virgen Del Camino (Pamplona), Espanha. METODOLOGIA: Estudo descritivo, retrospectivo, com análise de 297 bebes prematuros que estiveram internados na UTI neonatal e reinternaram em algum setor do hospital em questão pelo menos uma vez, em até 60 dias após sua alta. RESULTADOS: A maior parte dos casos (91, 25%) apresentaram uma única reinternação. O tempo médio de estadia na reinternação foi de 4, 61 dias. As principais causas que levaram a uma reinternação foram bronquites e asma sem complicações. CONCLUSÃO: Fazer com que os país permanesçam com seus filos em sua hospitalização podem proporciona-los maior conhecimento sobre o padrão de normalidade de seus filos, conhecer as principais doenças e os principais problemas asociados a prematuridade, fazendo com que os país procurem ajuda médica na fase inicial da doença, podemdo assim diminuir as chances de uma reinternação hospitalar
Asunto(s)
Humanos , Masculino , Femenino , Hospitalización/estadística & datos numéricos , Hospitalización/economía , Enfermedades del Recién Nacido/terapia , Enfermedades del Recién Nacido/economía , Readmisión del Paciente/economía , Readmisión del Paciente/estadística & datos numéricos , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/terapia , Estudios Retrospectivos , Factores de RiesgoRESUMEN
OBJECTIVES: To determine the impact of viral lower respiratory tract infections (LRTIs) in infancy including rhinovirus (RV) and infancy respiratory syncytial virus (RSV), on school age pulmonary function and healthcare utilization in prematurely born children. WORKING HYPOTHESIS: School age respiratory outcomes would be worse and healthcare utilization greater in children who had viral LRTIs in infancy. STUDY DESIGN: Prospective study. SUBJECT SELECTION: A cohort of prematurely born children who had symptomatic LRTIs during infancy documented, was recalled. METHODS: Pulmonary function was assessed at 5 to 7 years of age and health related costs of care from aged one to follow-up determined. RESULTS: Fifty-one children, median gestational age 33+6 weeks, were assessed at a median (IQR) age 7.03 (6.37-7.26) years. Twenty-one children had no LRTI, 14 RV LRTI, 10 RSV LRTI, and 6 another viral LRTI (other LRTI). Compared to the no LRTI group, the RV group had a lower FEV1 (P = 0.033) and the other LRTI group a lower FVC (P = 0.006). Non-respiratory medication costs were higher in the RV (P = 0.018) and RSV (P = 0.013) groups. Overall respiratory healthcare costs in the RV (£153/year) and RSV (£27/year) groups did not differ significantly from the no LRTI group (£56/year); the other LRTI group (£431/year) had higher respiratory healthcare costs (P = 0.042). CONCLUSIONS: In moderately prematurely born children, RV and RSV LRTIs in infancy were not associated with higher respiratory healthcare costs after infancy. Children who experienced LRTIs caused by other respiratory viruses (including RV) had higher respiratory healthcare costs and greater pulmonary function impairment.
Asunto(s)
Costos de la Atención en Salud , Enfermedades del Prematuro/economía , Recien Nacido Prematuro , Infecciones por Picornaviridae/economía , Infecciones por Virus Sincitial Respiratorio/economía , Rhinovirus , Niño , Preescolar , Femenino , Humanos , Recién Nacido , Enfermedades del Prematuro/epidemiología , Masculino , Aceptación de la Atención de Salud , Infecciones por Picornaviridae/epidemiología , Estudios Prospectivos , Infecciones por Virus Sincitial Respiratorio/epidemiologíaRESUMEN
The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of 472 compared to no prophylaxis (ICER 214,748/QALY). The ICER falls below a threshold of 80,000 per QALY when RSV prophylaxis cost would be lowered from 928 (baseline) to 406 per unit. At a unit cost of 97, RSV prophylaxis would be cost saving. CONCLUSIONS: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.
Asunto(s)
Antivirales/economía , Análisis Costo-Beneficio , Costos de la Atención en Salud/estadística & datos numéricos , Enfermedades del Prematuro/prevención & control , Palivizumab/economía , Infecciones por Virus Sincitial Respiratorio/prevención & control , Antivirales/uso terapéutico , Técnicas de Apoyo para la Decisión , Árboles de Decisión , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/diagnóstico , Enfermedades del Prematuro/economía , Masculino , Países Bajos , Palivizumab/uso terapéutico , Estudios Prospectivos , Años de Vida Ajustados por Calidad de Vida , Infecciones por Virus Sincitial Respiratorio/diagnóstico , Infecciones por Virus Sincitial Respiratorio/economía , Resultado del TratamientoRESUMEN
OBJECTIVE: To investigate the impact of social inequalities on the risk of rehospitalization in the first year after discharge from the neonatal unit in a population of preterm-born children. STUDY DESIGN: Preterm infants were included if they were born between 2006 and 2013 at ≤32 + 6 weeks of gestation and who received follow-up in a French regional medical network with a high level of healthcare. Socioeconomic context was estimated using a neighborhood-based socioeconomic deprivation index. Univariate and logistic regression analyses were used to identify risk factors associated with rehospitalization. RESULTS: For the 2325 children, the mean gestational age was 29 ± 2 weeks and the mean birth weight was 1315 ± 395 g. In the first year, 22% were rehospitalized (n = 589); respiratory diseases were the primary cause (44%). The multiple rehospitalization rate was 18%. Multivariable analysis showed that living in the most deprived neighborhoods (socioeconomic deprivation index of 5) was associated with overall rehospitalization (OR, 2.2; 95% CI, 1.5-3.6; P <.001), and multiple rehospitalizations (OR, 2.5; 95% CI, 1.2-4.9; P <.01); with socioeconomic deprivation index of 1 (least deprived) as reference. Deprivation was associated with all causes of hospitalization. Female sex (P <.001) and living in an urban area (P = .001) were protective factors. CONCLUSIONS: Despite regional routine follow-up for all children, rehospitalization after very preterm birth was higher for children living in deprived neighborhoods. Families' social circumstances need to be considered when evaluating the health consequences of very preterm birth.
Asunto(s)
Disparidades en el Estado de Salud , Enfermedades del Prematuro/etiología , Readmisión del Paciente/estadística & datos numéricos , Clase Social , Femenino , Estudios de Seguimiento , Francia , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/terapia , Modelos Logísticos , Masculino , Análisis Multivariante , Readmisión del Paciente/economía , Estudios Prospectivos , Factores de RiesgoRESUMEN
BACKGROUND: Care for infants born preterm or with major birth defects is costly. Specific estimates of financial burden for different payers are lacking, in part because use of administrative data to identify preterm infants and costs is challenging. METHODS: We used private health insurance claims data and billing codes to identify live births during 2013 and calculated first-year expenditures for employer-sponsored health plans for infants born preterm, both overall and stratified by major birth defects. RESULTS: We conservatively estimated that 7.7% of insured infants born preterm accounted for 37% of $2.0 billion spent by participating plans on the care of infants born during 2013. With a mean difference in plan expenditures of â¼$47 100 per infant, preterm births cost the included plans an extra $600 million during the first year of life. Extrapolating to the national level, we projected aggregate employer-sponsored plan expenditures of $6 billion for infants born preterm during 2013. Infants with major birth defects accounted for 5.8% of preterm births but 24.5% of expenditures during infancy. By using an alternative algorithm to identify preterm infants, it was revealed that incremental expenditures were higher: $78 000 per preterm infant and $14 billion nationally. CONCLUSION: Preterm births (especially in conjunction with major birth defects) represent a substantial burden on payers, and efforts to mitigate this burden are needed. In addition, researchers need to conduct studies using linked vital records, birth defects surveillance, and administrative data to accurately and longitudinally assess per-infant costs attributable to preterm birth and the interaction of preterm birth with major birth defects.
Asunto(s)
Anomalías Congénitas/economía , Planes de Asistencia Médica para Empleados/economía , Gastos en Salud/estadística & datos numéricos , Enfermedades del Prematuro/economía , Anomalías Congénitas/terapia , Bases de Datos Factuales , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/terapia , Estados UnidosRESUMEN
BACKGROUND: Necrotizing enterocolitis (NEC) is a costly gastrointestinal disorder that mainly affects preterm and low-birth-weight infants and can lead to considerable morbidity and mortality. Mother's own milk is protective against NEC but is not always available. In such cases, donor human milk has also been shown to be protective (although to a lesser extent) compared with formula milk, but it is more expensive. This systematic review aimed at evaluating the cost of donor milk, the cost of treating NEC, and the cost-effectiveness of exclusive donor milk versus formula milk feeding to reduce the short-term health and treatment costs of NEC. MATERIALS AND METHODS: We systematically searched five relevant databases to find studies with verifiable costs or charges of donor milk and/or treatment of NEC and any economic evaluations comparing exclusive donor milk with exclusive formula milk feeding. All search results were double screened. RESULTS: Seven studies with verifiable donor milk costs and 17 with verifiable NEC treatment costs were included. The types of cost or charge included varied considerably across studies, so quantitative synthesis was not attempted. Estimates of the incremental length of stay associated with NEC were â¼18 days for medical NEC and 50 days for surgical NEC. Two studies claimed to report economic evaluations but did not do so in practice. CONCLUSIONS: It is likely that donor milk provides short-term cost savings by reducing the incidence of NEC. Future studies should provide more details on cost components included and a full economic evaluation, including long-term outcomes, should be undertaken.
Asunto(s)
Enterocolitis Necrotizante/prevención & control , Enfermedades del Prematuro/prevención & control , Unidades de Cuidado Intensivo Neonatal/economía , Bancos de Leche Humana/economía , Leche Humana/inmunología , Análisis Costo-Beneficio , Enterocolitis Necrotizante/economía , Enterocolitis Necrotizante/inmunología , Humanos , Fenómenos Fisiológicos Nutricionales del Lactante , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/economía , Recién Nacido de muy Bajo PesoRESUMEN
BACKGROUND AND OBJECTIVE: Lower respiratory infections (LRIs) are among the most common reasons for pediatric hospitalization and among the diagnoses with the highest number of readmissions. Characterizing LRI readmissions would help guide efforts to prevent them. We assessed variation in pediatric LRI readmission rates, risk factors for readmission, and readmission diagnoses. METHODS: We analyzed 2008-2009 Medicaid Analytic eXtract data for patients <18 years of age in 26 states. We identified LRI hospitalizations based on a primary diagnosis of bronchiolitis, influenza, or community-acquired pneumonia or a secondary diagnosis of one of these LRIs plus a primary diagnosis of asthma, respiratory failure, or sepsis/bacteremia. Readmission rates were calculated as the proportion of hospitalizations followed by ≥1 unplanned readmission within 30 days. We used logistic regression with fixed effects for patient characteristics and a hospital random intercept to case-mix adjust rates and assess risk factors. RESULTS: Of 150 590 LRI hospitalizations, 8233 (5.5%) were followed by ≥1 readmission. The median adjusted hospital readmission rate was 5.2% (interquartile range: 5.1%-5.4%), and rates varied across hospitals (P < .0001). Infants (patients <1 year of age), boys, and children with chronic conditions were more likely to be readmitted. The most common primary diagnoses on readmission were LRIs (48.2%), asthma (10.0%), fluid/electrolyte disorders (3.4%), respiratory failure (3.3%), and upper respiratory infections (2.7%). CONCLUSIONS: LRI readmissions are common and vary across hospitals. Multiple risk factors are associated with readmission, indicating potential targets for strategies to reduce readmissions. Readmission diagnoses sometimes seem related to the original LRI.
Asunto(s)
Bronquiolitis/economía , Bronquiolitis/terapia , Infecciones Comunitarias Adquiridas/economía , Infecciones Comunitarias Adquiridas/terapia , Gripe Humana/economía , Gripe Humana/terapia , Medicaid/economía , Patient Protection and Affordable Care Act/economía , Readmisión del Paciente/economía , Neumonía/economía , Neumonía/terapia , Factores de Edad , Bronquiolitis/prevención & control , Infecciones Comunitarias Adquiridas/prevención & control , Control de Costos , Costos de la Atención en Salud , Hospitales Pediátricos/economía , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/prevención & control , Enfermedades del Prematuro/terapia , Gripe Humana/prevención & control , Neumonía/prevención & control , Factores de Riesgo , Estados UnidosRESUMEN
BACKGROUND: Small for gestational age (SGA) infants are at increased risk for preterm birth morbidities as well as a range of adverse perinatal outcomes that result in part from associated premature birth. We sought to evaluate the costs of SGA versus appropriate for gestational age (AGA) infants in France from pregnancy through the first year of life and separate the contributions of prematurity from the contribution of foetal growth on costs. METHODS: This is a cross-sectional population-based study using national hospital discharge data from French public and private hospitals. SGA infants were defined as newborns with a birth weight below the 10th percentile of French intrauterine growth curves adjusted for foetal sex. AGA infants were defined as newborns with a birth weight between the 25th and the 75th. All births were selected between January 1st, 2011 and December 31st, 2011. Costs were calculated from the hospital perspective for both mothers and children using their diagnostic related group and the French national cost study. Hospital outcomes were extracted from the database and compared by gestational age and mode of delivery. RESULTS: Of 777,720 total births in 2011, 84,688 SGA births (10.9%) and 395,760 AGA births (50.8%) were identified. After adjustment for gestational age, the cost for an SGA infant was 2,783 higher than for an AGA infant. The total maternal and infant hospital cost of SGA in France was estimated at 23% the total cost for deliveries. The high cost is explained by higher complication rates, more frequent hospital readmissions and longer lengths of stay. CONCLUSIONS: Being small for gestational age is an independent contributor to 1-year hospital costs for both mothers and infants.
Asunto(s)
Recien Nacido Prematuro , Recién Nacido Pequeño para la Edad Gestacional , Atención Perinatal/economía , Adulto , Peso al Nacer , Costos y Análisis de Costo , Estudios Transversales , Parto Obstétrico/economía , Femenino , Francia , Edad Gestacional , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/terapia , Tiempo de Internación/economía , Masculino , Morbilidad , Madres/estadística & datos numéricos , Embarazo , Factores SexualesRESUMEN
BACKGROUND: Early term birth is associated with increased need for hospital care during the early postnatal period. The objective of this study was to assess the morbidity and health care-related costs during the first 3 years of life in children born early term. METHODS: Data come from a population-based birth cohort study in the municipalities of Helsinki, Espoo, and Vantaa, Finland using data from the national medical birth register and outpatient, inpatient, and primary care registers. All surviving infants born in 2006-08 (n = 29 970) were included. The main outcome measures were morbidities, based on ICD-10 codes recorded during inpatient and outpatient hospital visits, and health care costs, based on all care received, including well child visits (specialised care, primary care, private care, and medications). RESULTS: 7.0% of children born full term had at least one of the studied morbidities by 3 years of age. This percentage was significantly higher in children born early term: 8.6% (adjusted odds ratio 1.2, 95% confidence interval (CI) 1.1, 1.4). The increased morbidity of children born early term was attributed to obstructive airway diseases and ophthalmological and motor problems. Health care-related costs during the first 3 years of life were 4813 (95% CI 4385, 5241) per child in the early term group, higher than for full term children 4047 (95% CI 3884, 4210). CONCLUSIONS: Infants born early term have increased morbidity and higher health care-related costs during early childhood than full term infants. Early term birth seems to be associated with a health disadvantage.
Asunto(s)
Enfermedades del Prematuro/economía , Nacimiento Prematuro/economía , Preescolar , Femenino , Finlandia/epidemiología , Edad Gestacional , Costos de la Atención en Salud , Humanos , Lactante , Cuidado del Lactante/economía , Recién Nacido , Enfermedades del Prematuro/epidemiología , Enfermedades del Prematuro/terapia , Morbilidad , Atención Perinatal/economía , Embarazo , Nacimiento Prematuro/epidemiología , Atención Primaria de Salud/economía , Sistema de RegistrosRESUMEN
BACKGROUND: In response to a national shortage of parenteral phosphorus solutions (2013), a hospital-wide phosphorus dose restriction strategies was implemented which included judicious use of phosphorus in preterm infants <1250âg birth weight and no parenteral phosphorus in preterm infants >1250âg birth weight unless they have a critically low phosphorus level. OBJECTIVE: To study the effect of parenteral phosphorus dose restriction in preterm infants admitted to the neonatal intensive care unit. METHODS: Preterm infants (≤35 weeks birth gestation and ≤2500âg birth weight) who received parenteral nutrition, survived >1 week and had no major congenital anomalies were studied. Clinical and laboratory data in the first 4 weeks of life of infants admitted during the parenteral phosphorus shortage (cases) were compared to infants who were admitted 6 months prior to the shortage (controls). RESULTS: Twenty consecutive cases were compared to 40 consecutive controls. Cases had lower serum phosphorus levels, higher serum alkaline phosphatase levels, and need for greater inotropic support compared to controls. These differences were significant only in preterm infants with birth weight >1250âg, the group who received more parenteral phosphorus dose restriction while they were similar in preterm infants with birth weight <1250âg. CONCLUSION: The modest effects of phosphorus dose restriction may become more clinically important if shortage is prolonged or severe or if it involves extreme preterm infants.
Asunto(s)
Asignación de Recursos para la Atención de Salud/economía , Enfermedades del Prematuro/prevención & control , Recien Nacido Prematuro , Unidades de Cuidado Intensivo Neonatal , Nutrición Parenteral/economía , Fósforo/administración & dosificación , Toma de Decisiones Clínicas , Femenino , Humanos , Recién Nacido , Enfermedades del Prematuro/economía , Unidades de Cuidado Intensivo Neonatal/economía , Masculino , Guías de Práctica Clínica como Asunto , Estudios Retrospectivos , Estados UnidosRESUMEN
OBJECTIVE: To estimate risk of necrotizing enterocolitis (NEC) for extremely low birth weight (ELBW) infants as a function of preterm formula (PF) and maternal milk intake and calculate the impact of suboptimal feeding on the incidence and costs of NEC. STUDY DESIGN: We used aORs derived from the Glutamine Trial to perform Monte Carlo simulation of a cohort of ELBW infants under current suboptimal feeding practices, compared with a theoretical cohort in which 90% of infants received at least 98% human milk. RESULTS: NEC incidence among infants receiving ≥98% human milk was 1.3%; 11.1% among infants fed only PF; and 8.2% among infants fed a mixed diet (P = .002). In adjusted models, compared with infants fed predominantly human milk, we found an increased risk of NEC associated with exclusive PF (aOR = 12.1, 95% CI 1.5, 94.2), or a mixed diet (aOR 8.7, 95% CI 1.2-65.2). In Monte Carlo simulation, current feeding of ELBW infants was associated with 928 excess NEC cases and 121 excess deaths annually, compared with a model in which 90% of infants received ≥98% human milk. These models estimated an annual cost of suboptimal feeding of ELBW infants of $27.1 million (CI $24 million, $30.4 million) in direct medical costs, $563â655 (CI $476â191, $599â069) in indirect nonmedical costs, and $1.5 billion (CI $1.3 billion, $1.6 billion) in cost attributable to premature death. CONCLUSIONS: Among ELBW infants, not being fed predominantly human milk is associated with an increased risk of NEC. Efforts to support milk production by mothers of ELBW infants may prevent infant deaths and reduce costs.
Asunto(s)
Lactancia Materna/economía , Enterocolitis Necrotizante/economía , Costos de la Atención en Salud/estadística & datos numéricos , Fórmulas Infantiles/economía , Recien Nacido con Peso al Nacer Extremadamente Bajo , Enfermedades del Prematuro/economía , Enterocolitis Necrotizante/epidemiología , Enterocolitis Necrotizante/prevención & control , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/epidemiología , Enfermedades del Prematuro/prevención & control , Leche Humana , Modelos Económicos , Método de Montecarlo , Estados Unidos/epidemiologíaAsunto(s)
Cuidado Intensivo Neonatal/economía , Óxido Nítrico/administración & dosificación , Administración por Inhalación , Costos y Análisis de Costo , Humanos , Hipoxia/economía , Hipoxia/terapia , Recién Nacido , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/terapia , Unidades de Cuidado Intensivo Neonatal , Óxido Nítrico/economía , Insuficiencia Respiratoria/economía , Insuficiencia Respiratoria/terapiaRESUMEN
BACKGROUND: Recurrent wheezing in young infants has a high prevalence, influences quality of life, and generates substantial health care costs. We previously showed that respiratory syncytial virus infection is an important mechanism of recurrent wheezing in moderate preterm infants. We aimed to provide population-attributable risks (PAR) of risk factors for recurrent wheezing during the first year of life in otherwise healthy moderate preterm infants. METHODS: RISK is a multicentre prospective birth cohort study of 4424 moderate preterm infants born at 32-35 weeks gestation. We estimated PAR of risk factors for recurrent wheezing, which was defined as three or more parent-reported wheezing episodes during the first year of life. RESULTS: We evaluated 3952 (89%) children at 1 year of age, of whom 705 infants (18%) developed recurrent wheezing. Fourteen variables were independently associated with recurrent wheezing. Hospitalisation for respiratory syncytial virus bronchiolitis had a strong relationship with recurrent wheezing (RR 2.6; 95% confidence interval, CI, 2.2, 3.1), but a relative modest PAR (8%; 95% CI 6, 11%) which can be explained by a low prevalence (13%). Day-care attendance showed a strong relationship with recurrent wheezing (RR 1.9; 95% CI 1.7, 2.2) and the highest PAR (32%; 95% CI 23, 37%) due to a high prevalence (67%). The combined adjusted PAR for the 14 risk factors associated with recurrent wheezing was 49% (95% CI 46, 52%). CONCLUSIONS: In moderate preterm infants, day-care attendance has the largest PAR for recurrent wheezing. Trial evidence is needed to determine the potential benefit of delayed day-care attendance in this population.
Asunto(s)
Bronquiolitis/epidemiología , Hospitalización/estadística & datos numéricos , Enfermedades del Prematuro/epidemiología , Ruidos Respiratorios/fisiopatología , Infecciones por Virus Sincitial Respiratorio/epidemiología , Bronquiolitis/economía , Bronquiolitis/fisiopatología , Preescolar , Análisis Costo-Beneficio , Femenino , Estudios de Seguimiento , Hospitalización/economía , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/etiología , Enfermedades del Prematuro/fisiopatología , Masculino , Estudios Prospectivos , Calidad de Vida , Recurrencia , Infecciones por Virus Sincitial Respiratorio/economía , Infecciones por Virus Sincitial Respiratorio/fisiopatología , Factores de Riesgo , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Marked progress in neonatology changed care of very preterm infants (VLBW) over the last decades - but also the attitude towards family-centred care (FCC). With the directive of the German Federal Joined Committee (G-BA), politicians recognize the necessity of neonatal FCC. AIM: To evaluate time and personnel costs necessary at a centre of established FCC. METHODS: Elternberatung "Frühstart" is a FCC programme for VLBW and seriously ill neonates from preganancy at risk to follow-up home-visits delivered by one interdisciplinary team. Analysis (2011-2014): 1.) Number of cases /participation in programme, 2.) resources of time, 3) and personnel, 4.) funding, 5) economic impact. RESULTS: 1.1.2011-31.12.2014: 441 cases (total cases: 2 212) participated in the programme. Participation of VLBW: mean 92% (86.4-97,2%). Costs of time are highest in neonates with congenital malformations: median 13.8 h, VLBW: median 11,2 h. Transition to home is most time intensive: median 7,3 (0-42.5) h. In average of 3.1 full-time nurses (part-time workers) are able to counsel 48 families/quarter. In severe cases funding is partly provided by health care insurances for social medical aftercare: positive applications: mean 92.7% (79.6-97.7%). CONCLUSION: Participation in the FCC programme in neonatology is high and costs of time are manageable.
Asunto(s)
Anomalías Congénitas/economía , Anomalías Congénitas/enfermería , Enfermería de la Familia/economía , Costos de la Atención en Salud/estadística & datos numéricos , Visita Domiciliaria/economía , Enfermedades del Prematuro/economía , Enfermedades del Prematuro/enfermería , Recién Nacido de muy Bajo Peso , Anomalías Congénitas/epidemiología , Análisis Costo-Beneficio/estadística & datos numéricos , Educación no Profesional/economía , Educación no Profesional/estadística & datos numéricos , Enfermería de la Familia/estadística & datos numéricos , Femenino , Alemania , Recursos en Salud/economía , Recursos en Salud/estadística & datos numéricos , Visita Domiciliaria/estadística & datos numéricos , Humanos , Recién Nacido , Enfermedades del Prematuro/epidemiología , Comunicación Interdisciplinaria , Colaboración Intersectorial , Masculino , Programas Nacionales de Salud/economía , Programas Nacionales de Salud/estadística & datos numéricosRESUMEN
The global burden of preterm birth (PTB) includes the morbidity and mortality of babies born before 37 completed weeks of gestation. Prematurity has been the leading worldwide cause of neonatal mortality for at least a decade, but has now also become the leading cause of childhood mortality through age five years. Globally, each year, 15 million babies are born preterm, which is estimated to be about 11% of all deliveries. Preterm birth appears to be increasing in most countries. This review will address the epidemiology, rates, and etiology of PTB around the globe as well as survival by gestational age and interventions and preventative measures known to improve outcomes in high-burden countries.